

BSA Ad Hoc Subcommittee for the “The Childhood Cancer Therapeutically Applicable Research to Generate Effective Treatments (TARGET)” Initiative

Mission Statement

This BSA Ad hoc subcommittee provides advice and oversight of the proactive NCI efforts to systematically apply a set of state-of-the-art methods to childhood cancer tumor specimens with the focused objective of identifying new therapeutic targets that can be exploited to improve outcome for children with cancer.

A public-private partnership agreement (Memorandum of Understanding) between the Foundation for the National Institutes of Health, Inc. and the National Cancer Institute shall be used to support the identification and validation of therapeutic targets for childhood cancers. This initiative is important because current treatment approaches have reached a plateau in improving outcome for children with cancer, and the introduction of targeted agents in the childhood cancer setting will benefit children only if they are utilized with a sound knowledge of relevant therapeutic targets for specific pediatric cancers.

The three initial areas of research focus are:

1. Application of high-throughput, cost-effective technologies to map and characterize comprehensively genomic and/or transcriptomic and/or epigenomic alterations.
2. Application of targeted high-throughput resequencing to identify genes or chromosome regions that are consistently mutated in specific childhood cancers. Genes or chromosome regions will be selected for resequencing based in large measure on the data generated through the genomic characterization research described above.
3. Application of high-throughput RNAi and small molecular screening methods to identify and validate therapeutic targets.

This ad hoc subcommittee shall be composed of scientists and advocates with expertise covering the three priority areas in order to provide direction and management of the initiative.

**Board of Scientific Advisors Ad Hoc Subcommittee for the Childhood Cancer
Therapeutically Applicable Research to Generate Effective Treatment (TARGET)
Initiative**

CHAIR

Joe W. Gray, Ph.D.

Director

Division of Life Sciences

Associate Director, Biosciences

Lawrence Berkeley National Laboratory

Berkeley, CA 94720

MEMBERS

John D. Carpten, Ph.D.

Senior Investigator and Director for Integrated
Cancer Genomics Division
Translational Genomics Research Institute
Phoenix, AZ 85014

William Evans, Ph.D.

Director, St. Jude Children's Research Hospital
Memphis, TN 38105

Todd R. Golub, M.D.

Associate Professor
Cancer Program
The Broad Institute of Massachusetts Institute
of Technology and Harvard University
Cambridge, MA 02142

Greg Hannon, Ph.D.

Professor
Cold Spring Harbor Laboratory
Watson School of Biological Sciences
Cold Spring Harbor, NY 11724

Mary J. Hendrix, Ph.D.

President and Scientific Director
Children's Memorial Research Center
Professor of Pediatrics
Feinberg School of Medicine
Northwestern University
Chicago, IL 60614-3394

Ruth Hoffman, MPH

Advocate
Kensington, MD 20895

Michael P. Link, M.D.

Chief
Division of Hematology/Oncology and
Bone Marrow Transplantation
Professor of Pediatrics
Stanford University School of Medicine
Palo Alto, CA 94304

Philip A. Pizzo, M.D.

Carl and Elizabeth Naumann Dean of the School
of Medicine
Professor of Pediatrics and of Microbiology and
Immunology
Stanford University School of Medicine
Stanford, CA 94305

Gregory H. Reaman, M.D.

Professor of Pediatrics
Children's Oncology Group - Operations Center
Bethesda, MD 20814

Stephen P. Spielberg M.D., Ph.D.

Professor Pediatrics, and of Pharmacology
and Toxicology
Dartmouth Medical School
Hanover, NH 03755

Susan L. Weiner, Ph.D.

President
Children's Cause for Cancer Advocacy
Brooklyn, NY 11215

EXECUTIVE SECRETARY

Malcolm Smith, M.D., Ph.D.

Associate Branch Chief, Pediatrics
Cancer Therapy Evaluation Program, NCI
Bethesda, MD 20892